Skip to main content
ENVB
NASDAQ Life Sciences

Enveric Reports Q2 Loss of $3.0M, $8.3M Cash, and $6.5M in New Financing

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$1.535
Mkt Cap
$5.652M
52W Low
$1.25
52W High
$17.64
52W Position info
23% above low
Off High info
91% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

ENVB sits 23% above its 52-week low of $1.25 on light trading volume (0.3× avg).

Summary

Enveric reported a $3.0M Q2 net loss with $8.3M cash on hand, and disclosed $6.5M in new financing from a private placement and warrant exercises.


Key Events · Earnings and Guidance · ENVB

  • Q2 Net Loss Widens

    Net loss attributable to stockholders was $3.0 million for Q2 2026, up from $2.5 million in Q2 2025. Loss per share improved to $0.76 from $11.65 due to the reverse split.

  • Cash Position at $8.3M

    Cash-on-hand was $8.3 million as of June 30, 2026, providing limited runway given the going concern warning and ongoing operating losses.

  • New Financing Totals $6.5M

    Closed a private placement for approximately $5.0 million in upfront gross proceeds, with potential for up to $8.9 million more if warrants are exercised. Raised an additional $1.5 million from warrant exercises.

  • IP Portfolio Strengthened

    Received a USPTO Notice of Allowance for the EVM401 Series and secured U.S. Patent No. 12,605,361 for the EVM301 Series, expanding protection around neuroplastogen candidates.


Analysis · ENVB · Life Sciences

The second quarter saw Enveric's net loss widen to $3.0 million from $2.5 million a year earlier, though the per-share loss improved sharply to $0.76 from $11.65 thanks to the reverse split. With only $8.3 million in cash at quarter-end, the going concern warning looms large. The $5.0 million private placement and $1.5 million in warrant exercises offer near-term runway but come with dilution. Meanwhile, the patent allowance and new patent bolster the IP around EB-003, yet the financial footing remains shaky.

How filings like this one have moved

In the 30 days to Nov 5, 2026, 33.4% of the 2397 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ENVB was trading at $1.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.7M. The 52-week trading range was $1.25 to $17.64. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ENVB - Latest Insights

ENVB
Aug 14, 2026, 4:21 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.54
Real-time Price: $1.40 info
Change: -$0.135 (-9%) info
Market Cap: $6.266M info
ENVB
Aug 05, 2026, 8:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $1.67
Real-time Price: $1.40 info
Change: -$0.2685 (-16%) info
Market Cap: $6.266M info
ENVB
Jun 09, 2026, 5:15 PM EDT
Filing Type: 424B5
Importance Score:
9
Price at Filing: $1.63
Real-time Price: $1.40 info
Change: -$0.230 (-14%) info
Market Cap: $6.266M info
ENVB
Jun 08, 2026, 5:53 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.71
Real-time Price: $1.40 info
Change: -$0.310 (-18%) info
Market Cap: $6.266M info
ENVB
Jun 02, 2026, 8:04 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $2.20
Real-time Price: $1.40 info
Change: -$0.800 (-36%) info
Market Cap: $6.266M info